NVO Novo Nordisk A/S

61.08
-0.51  -1%
Previous Close 61.59
Open 62.06
Price To Book 18.23
Market Cap 143,608,697,107
Shares 2,351,157,451
Volume 2,028,406
Short Ratio 3.72
Av. Daily Volume 1,482,693
Stock charts supplied by TradingView

NewsSee all news

  1. Novo Nordisk's new insulin affordability offerings now available in the US

    PLAINSBORO, N.J., Jan. 2, 2020 /PRNewswire/ -- Today, Novo Nordisk launched the My$99Insulin Program, follow-on brands of insulins, and an Immediate Supply option, expanding its insulin affordability offering to help

  2. New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic

    PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of

  3. New international study: The hidden burden of diabetes on family members revealed

    New international study shows 64 per cent of family members of peoplewith diabetes are worried or anxious about the risk of low blood sugar MISSISSAUGA, ON, Sept. 10, 2019 /CNW/ - People

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced September 20, 2019.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 data due 1H 2021.
Concizumab - Explorer 7
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial initiated 2Q 2019.
Somapacitan (NN8640)
Growth Hormone Deficiency (GHD)
Phase 2 data released 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Semaglutide
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
N8-GP
Hemophilia A
Phase 2 trial initiated 1Q 2019.
AM833
Obesity

Latest News

  1. Novo Nordisk's new insulin affordability offerings now available in the US

    PLAINSBORO, N.J., Jan. 2, 2020 /PRNewswire/ -- Today, Novo Nordisk launched the My$99Insulin Program, follow-on brands of insulins, and an Immediate Supply option, expanding its insulin affordability offering to help

  2. New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic

    PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of

  3. New international study: The hidden burden of diabetes on family members revealed

    New international study shows 64 per cent of family members of peoplewith diabetes are worried or anxious about the risk of low blood sugar MISSISSAUGA, ON, Sept. 10, 2019 /CNW/ - People